Key result
Drugs targeting the Renin-Angiotensin System, such as ACE inhibitors and AT1 receptor antagonists, show potential as symptomatic and neuroprotective therapies for Parkinson's disease.
Why the study?
Do drugs targeting the Renin-Angiotensin System provide symptomatic or neuroprotective effects in Parkinson's disease?
Population
Parkinson's disease patients and animal models
Design
Review
Authors
Loading...
May support RAS modulation for symptomatic and neuroprotective effects in Parkinson's disease; leaves open confirmation in randomized trials.
Do drugs targeting the Renin-Angiotensin System provide symptomatic or neuroprotective effects in Parkinson's disease?
The renin-angiotensin system represents a promising target for both symptomatic and neuroprotective therapies in Parkinson's disease, warranting further clinical investigation.
Perez‐Lloret et al. (2017) conducted a review in Parkinson's disease. Drugs targeting the Renin-Angiotensin System (RAS) was evaluated. Drugs targeting the Renin-Angiotensin System, such as ACE inhibitors and AT1 receptor antagonists, show potential as symptomatic and neuroprotective therapies for Parkinson's disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: